BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26476230)

  • 1. Novel Treatment Concepts in Psoriatic Arthritis.
    Boyd T; Kavanaugh A
    Rheum Dis Clin North Am; 2015 Nov; 41(4):739-54. PubMed ID: 26476230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to biological therapy for psoriatic arthritis.
    Boyd T; Kavanaugh A
    Expert Opin Biol Ther; 2016; 16(2):173-86. PubMed ID: 26572089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.
    Torre Alonso JC; Díaz Del Campo Fontecha P; Almodóvar R; Cañete JD; Montilla Morales C; Moreno M; Plasencia-Rodríguez C; Ramírez García J; Queiro R
    Reumatol Clin (Engl Ed); 2018; 14(5):254-268. PubMed ID: 29111261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic Therapy for Psoriatic Arthritis.
    Mease PJ
    Rheum Dis Clin North Am; 2015 Nov; 41(4):723-38. PubMed ID: 26476229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriatic arthritis: current therapy and future approaches.
    Huynh D; Kavanaugh A
    Rheumatology (Oxford); 2015 Jan; 54(1):20-8. PubMed ID: 25125588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical remission in rheumatoid arthritis and psoriatic arthritis.
    Lubrano E; Mesina F; Caporali R
    Clin Exp Rheumatol; 2018; 36(5):900-910. PubMed ID: 29600949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriatic arthritis: current therapy and future directions.
    Huynh D; Kavanaugh A
    Expert Opin Pharmacother; 2013 Sep; 14(13):1755-64. PubMed ID: 23815157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriatic arthritis: new evidence for old concepts.
    Soriano ER; Marin J; Acosta-Felquer ML
    Curr Opin Rheumatol; 2018 Jan; 30(1):87-93. PubMed ID: 29035933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
    Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
    J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
    Soriano ER
    Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.
    Ballegaard C; Jørgensen TS; Skougaard M; Strand V; Mease PJ; Kristensen LE; Dreyer L; Gottlieb A; de Wit M; Christensen R; Tarp S
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1206-1217. PubMed ID: 29073353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of disease activity measures for psoriatic arthritis: what is the best approach?
    Her M; Kavanaugh A
    Expert Rev Clin Immunol; 2014 Sep; 10(9):1241-54. PubMed ID: 25088300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosing and treating psoriatic arthritis: an update.
    Boehncke WH; Qureshi A; Merola JF; Thaçi D; Krueger GG; Walsh J; Kim N; Gottlieb AB
    Br J Dermatol; 2014 Apr; 170(4):772-86. PubMed ID: 24266754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
    Saad AA; Hyrich KL; Ashcroft DM
    Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.